Ageing and neurodegenerative diseases

Ageing Research Reviews

Volumn 9, Issue SUPPL., 2010, Pages

  Hung, Chia Wei ^a,c   Chen, Yu Chih ^b,c   Hsieh, Wan Ling ^b   Chiou, Shih Hwa ^b,c   Kao, Chung Lan ^b,c  

^a Zhongxiao Branch   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Neural stem cells; Neurodegenerative diseases; Neuroprotection; Stem cell based strategy; Stem cells

Indexed keywords

RESVERATROL;

AGED; AGING; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; DEGENERATIVE DISEASE; DEPRESSION; DIET SUPPLEMENTATION; DRUG EFFECT; ENVIRONMENTAL FACTOR; EXERCISE; FRAIL ELDERLY; HEREDITY; HUMAN; METAZOON; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; REVIEW; STEM CELL TRANSPLANTATION; STROKE; VERTEBRATE;

AGING; ANTIOXIDANTS; HUMANS; LONGEVITY; NEURODEGENERATIVE DISEASES; STILBENES;

EID: 77957952186     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2010.08.006     Document Type: Review

References (190)

1. Abe J., Kusuhara M., Ulevitch R.J., Berk B.C., Lee J.D. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem. 1996, 271:16586-16590.
2. Ahmed A., Tollefsbol T. Telomeres and telomerase: basic science implications for aging. J. Am. Geriatr. Soc. 2001, 49:1105-1109.
3. Albani D., Polito L., Batelli S., De Mauro S., Fracasso C., et al. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J. Neurochem. 2009, 110:1445-1456.
4. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence?. Nat. Med. 2004, 10(Suppl.):S18-S25.
5. Andrews-Hanna J.R., Snyder A.Z., Vincent J.L., Lustig C., Head D., et al. Disruption of large-scale brain systems in advanced aging. Neuron 2007, 56:924-935.
6. Arumugam T.V., Phillips T.M., Cheng A., Morrell C.H., Mattson M.P., et al. Age and energy intake interact to modify cell stress pathways and stroke outcome. Ann. Neurol. 2010, 67:41-52.
7. Arvidsson A., Collin T., Kirik D., Kokaia Z., Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat. Med. 2002, 8:963-970.
8. Aviv A. Telomeres and human aging: facts and fibs. Sci. Aging Knowledge Environ. 2004, pe43.
9. Ay H., Koroshetz W.J., Vangel M., Benner T., Melinosky C., et al. Conversion of ischemic brain tissue into infarction increases with age. Stroke 2005, 36:2632-2636.
10. 2- in vascular smooth muscle cells. Circ. Res. 1995, 77:29-36.
11. Barger J.L., Walford R.L., Weindruch R. The retardation of aging by caloric restriction: its significance in the transgenic era. Exp. Gerontol. 2003, 38:1343-1351.
12. Bauer M.E. Chronic stress and immunosenescence: a review. Neuroimmunomodulation 2008, 15:241-250.
13. Bauer J.H., Goupil S., Garber G.B., Helfand S.L. An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:12980-12985.
14. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5:493-506.
15. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
16. Bishop N.A., Lu T., Yankner B.A. Neural mechanisms of ageing and cognitive decline. Nature 2010, 464:529-535.
17. Blander, G., Guarente, L., 2004. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73 (2994) 417-435.
18. Boelen M. The role of rehabilitative modalities and exercise in Parkinson's disease. Dis. Mon. 2007, 53:259-264.
19. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
20. Braak H., Bohl J.R., Muller C.M., Rub U., de Vos R.A., et al. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord. 2006, 21:2042-2051.
21. Brederlau A., Correia A.S., Anisimov S.V., Elmi M., Paul G., et al. Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: effect of in vitro differentiation on graft survival and teratoma formation. Stem Cells 2006, 24:1433-1440.
22. Brown E.S., Varghese F.P., McEwen B.S. Association of depression with medical illness: does cortisol play a role?. Biol. Psychiatry 2004, 55:1-9.
23. Busse E.W. Hypochondriasis in the elderly. Compr. Ther. 1987, 13:37-42.
24. Campbell S., Marriott M., Nahmias C., MacQueen G.M. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 2004, 161:598-607.
25. Chaudhary N., Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12:431-437.
26. Chen H., Pandey G.N., Dwivedi Y. Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport 2006, 17:863-867.
27. Chen S.J., Kao C.L., Chang C.L., Yen C.J., Shui J.W., et al. Antidepressant administration modulates neural stem cell survival and serotoninergic differentiation through bcl-2. Curr. Neurovasc. Res. 2007, 4:19-29.
28. Chiou S.H., Chen S.J., Peng C.H., Chang Y.L., Ku H.H., et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem. Biophys. Res. Commun. 2006, 343:391-400.
29. Chiou S.H., Ku H.H., Tsai T.N., Lin H.L., Chen L.H., et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br. J. Pharmacol. 2006, 148:587-598.
30. Chodosh J., Kado D.M., Seeman T.E., Karlamangla A.S. Depressive symptoms as a predictor of cognitive decline: MacArthur Studies of Successful Aging. Am. J. Geriatr. Psychiatry 2007, 15:406-415.
31. Chung S., Shin B.S., Hedlund E., Pruszak J., Ferree A., et al. Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J. Neurochem. 2006, 97:1467-1480.
32. Cohen B.S. Geriatric rehabilitation. Am. Family Physician 1984, 30:133-137.
33. Do G.M., Kwon E.Y., Kim H.J., Jeon S.M., Ha T.Y., et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem. Biophys. Res. Commun. 2008, 374:55-59.
34. Doherty T.M. Physiology of aging invited review: aging and sarcopenia. J. Appl. Physiol. 2003, 95:1717-1727.
35. Durham H.D., Roy J., Dong L., Figlewicz D.A. Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. 1997, 56:523-530.
36. Epel E., Daubenmier J., Moskowitz J.T., Folkman S., Blackburn E. Can meditation slow rate of cellular aging? Cognitive stress, mindfulness, and telomeres. Ann. NY Acad. Sci. 2009, 1172:34-53.
37. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
38. Evans D.L., Charney D.S., Lewis L., Golden R.N., Gorman J.M., et al. Mood disorders in the medically ill: scientific review and recommendations. Biol. Psychiatry 2005, 58:175-189.
39. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991, 114(Pt 5):2283-2301.
40. Ferrara N., Rinaldi B., Corbi G., Conti V., Stiuso P., Boccuti S., Rengo G., Rossi F., Filippelli A. Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 2008, 11:139-150.
41. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
42. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
43. Frojdo S., Durand C., Pirola L. Metabolic effects of resveratrol in mammals-a link between improved insulin action and aging. Curr. Aging Sci. 2008, 1:145-151.
44. Frontera W.R., Hughes V.A., Lutz K.J., Evans W.J. A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. J. Appl. Physiol. 1991, 71:644-650.
45. Frye R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 1999, 260:273-279.
46. Fu W., Lu C., Mattson M.P. Telomerase mediates the cell survival-promoting actions of brain-derived neurotrophic factor and secreted amyloid precursor protein in developing hippocampal neurons. J. Neurosci. 2002, 22:10710-10719.
47. Gaczynska M., Osmulski P.A., Ward W.F. Caretaker or undertaker? The role of the proteasome in aging. Mech. Ageing Dev. 2001, 122:235-254.
48. Gage F.H. Mammalian neural stem cells. Science 2000, 287:1433-1438.
49. Glavaski-Joksimovic A., Virag T., Chang Q.A., West N.C., Mangatu T.A., McGrogan M.P., Dugich-Djordjevic M., Bohn M.C. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors. Cell Transplant 2009, 18:801-814.
50. Goldman S. Stem and progenitor cell-based therapy of the human central nervous system. Nat. Biotechnol. 2005, 23:862-871.
51. Gomez-Isla T., Price J.L., McKeel D.W., Morris J.C., Growdon J.H., et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996, 16:4491-4500.
52. Griffin L.D., Mellon S.H. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:13512-13517.
53. Gruber J., Tang S.Y., Halliwell B. Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann. NY Acad. Sci. 2007, 1100:530-542.
54. Guillaume D.J., Johnson M.A., Li X.J., Zhang S.C. Human embryonic stem cell-derived neural precursors develop into neurons and integrate into the host brain. J. Neurosci. Res. 2006, 84:1165-1176.
55. Gump B.B., Matthews K.A., Eberly L.E., Chang Y.F. Depressive symptoms and mortality in men: results from the Multiple Risk Factor Intervention Trial. Stroke 2005, 36:98-102.
56. Gurvits T.V., Shenton M.E., Hokama H., Ohta H., Lasko N.B., et al. Magnetic resonance imaging study of hippocampal volume in chronic, combat-related posttraumatic stress disorder. Biol. Psychiatry 1996, 40:1091-1099.
57. Haigis M.C., Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20:2913-2921.
58. Halliday G.M., McCann H. The progression of pathology in Parkinson's disease. Ann. NY Acad. Sci. 2010, 1184:188-195.
59. Hashimoto K., Shimizu E., Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res. Brain Res. Rev. 2004, 45:104-114.
60. Hedlund E., Perlmann T. Neuronal cell replacement in Parkinson's disease. J. Intern. Med. 2009, 266:358-371.
61. Hedlund E., Pruszak J., Lardaro T., Ludwig W., Vinuela A., et al. Embryonic stem cell-derived Pitx3-enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 2008, 26:1526-1536.
62. Heuser I. Depression, endocrinologically a syndrome of premature aging?. Maturitas 2002, 41(Suppl. 1):S19-S23.
63. Hillman C.H., Erickson K.I., Kramer A.F. Be smart, exercise your heart: exercise effects on brain and cognition. Nature 2008, 9:58-65.
64. Hindle J.V. Ageing, neurodegeneration and Parkinson's disease. Age Ageing 2010, 39:156-161.
65. Howitz K.T., Bitterman K.J., Cohen H.Y., Lamming D.W., Lavu S., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425:191-196.
66. Huang C.J., Cheng H.H., Chou C.T., Kuo C.C., Lu Y.C., et al. Desipramine-induced Ca2+ movement and cytotoxicity in PC3 human prostate cancer cells. Toxicol. In Vitro 2007, 21:449-456.
67. Hwang J.T., Kwon D.Y., Park O.J., Kim M.S. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2008, 2:323-326.
68. Imai S., Armstrong C.M., Kaeberlein M., Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000, 403:795-800.
69. Ito K., Hirao A., Arai F., Takubo K., Matsuoka S., et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 2006, 12:446-451.
70. Jaliffa C., Ameqrane I., Dansault A., Leemput J., Vieira V., et al. Sirt1 involvement in rd10 mouse retinal degeneration. Invest. Ophthalmol. Vis. Sci. 2009, 50:3562-3572.
71. Jin F., Wu Q., Lu Y.F., Gong Q.H., Shi J.S. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. Eur. J. Pharmacol. 2008, 600:78-82.
72. Johnson J.A., Majumdar S.R., Simpson S.H., Toth E.L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002, 25:2244-2248.
73. Joseph J.A., Shukitt-Hale B., Casadesus G., Fisher D. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem. Res. 2005, 30:927-935.
74. Kaeberlein M., McVey M., Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev. 1999, 13:2570-2580.
75. Kao C.L., Huang P.I., Tsai P.H., Tsai M.L., Lo J.F., et al. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:219-228.
76. Kao C.L., Tai L.K., Chiou S.H., Chen Y.J., Lee K.H., et al. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem Cells Dev. 2010, 19:247-258.
77. Kao, C.L., Chen, L.K., Chang, Y.L., Yua, M.C., Hsu, C.C., et al. Reseveratrol protects human endothelium from H2O2 induced oxidative stress and senescence via SirT1 activation, J. Atheroscler. Thromb., in press.
78. Kaufman J., Yang B.Z., Douglas-Palumberi H., Grasso D., Lipschitz D., et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol. Psychiatry 2006, 59:673-680.
79. Kempermann G., Krebs J., Fabel K. The contribution of failing adult hippocampal neurogenesis to psychiatric disorders. Curr. Opin. Psychiatry 2008, 21:290-295.
80. Khanzode S.D., Dakhale G.N., Khanzode S.S., Saoji A., Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep. 2003, 8:365-370.
81. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007, 26:3169-3179.
82. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 1995, 332:1118-1124.
83. Kottke F.J., Lehmann J.F. Krusen's Handbook of Physical Medicine and Rehabilitation 1990, W. B. Saunders Co., Philadelphia. 4th ed.
84. Kramer A.F., Erickson S.I. Effects of physical activity on cognition, well-being, and brain: humans interventions. Alzheimers Dement 2007, 3:S45-S51.
85. Kramer A.F., Colcombe S.J., McAuley E., Scalf P.E., Erickson K.I., et al. Fitness, aging and neurocognitive function. Neurobiol. Aging 2005, 26(Suppl.):S124-S127.
86. Kukull W.A., Higdon R., Bowen J.D., McCormick W.C., Teri L., et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 2002, 59:1737-1746.
87. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
88. Lee H.J., Kim J.W., Yim S.V., Kim M.J., Kim S.A., et al. Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol. Psychiatry 2001, 6:618-725.
89. Liao F., Andalibi A., Qiao J.H., Allayee H., Fogelman A.M., et al. Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J. Clin. Invest. 1994, 94:877-884.
90. Lin S.J., Defossez P.A., Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000, 289:2126-2128.
91. Lin H.Y., Sun M., Tang H.Y., Simone T.M., Wu Y.H., et al. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J. Cell. Biochem. 2008, 104:2131-2142.
92. Lindvall O., Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Prog. Brain Res. 2000, 127:299-320.
93. Lindvall O., Kokaia Z., Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders-how to make it work. Nat. Med. 2004, 10 Suppl.:S42-S50.
94. Liu F., Akella P., Benashski S.E., Xu Y., McCullough L.D. Expression of Na-K-Cl cotransporter and edema formation are age dependent after ischemic stroke. Exp. Neurol. 2010, 224:356-361.
95. Loerch P.M., Lu T., Dakin K.A., Vann J.M., Isaacs A., et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS One 2008, 3:e3329.
96. Lotito S.B., Frei B. Consumption of flavonoid-rich foods and increased plasma antioxidant capacity in humans: cause, consequence, or epiphenomenon?. Free Radic. Biol. Med. 2006, 41:1727-1746.
97. Louis E.D., Bennett D.A. Mild Parkinsonian signs: an overview of an emerging concept. Mov. Disord. 2007, 22:1681-1688.
98. Lu T., Pan Y., Kao S.Y., Li C., Kohane I., et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429:883-891.
99. Macciocchi S.N., Diamond P.T., Alves W.M., Mertz T. Ischemic stroke: relation of age, lesion location, and initial neurologic deficit to functional outcome. Arch. Phys. Med. Rehabil. 1998, 79:1255-1257.
100. Mancuso C., Bates T.E., Butterfield D.A., Calafato S., Cornelius C., et al. Natural antioxidants in Alzheimer's disease. Expert Opin. Investig. Drugs 2007, 16:1921-1931.
101. McCusker J., Cole M., Ciampi A., Latimer E., Windholz S., et al. Major depression in older medical inpatients predicts poor physical and mental health status over 12 months. Gen. Hosp. Psychiatry 2007, 29:340-348.
102. McIntyre R.S., Soczynska J.K., Konarski J.Z., Woldeyohannes H.O., Law C.W., et al. Should depressive syndromes be reclassified as " Metabolic Syndrome Type II" ?. Ann. Clin. Psychiatry 2007, 19:257-264.
103. McIntyre R.S., Rasgon N.L., Kemp D.E., Nguyen H.T., Law C.W., et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr. Diab. Rep. 2009, 9:51-59.
104. Morselli E., Galluzzi L., Kepp O., Criollo A., Maiuri M.C., et al. Autophagy mediates pharmacological lifespan extension by spermidine and resveratrol. Aging (Albany NY) 2009, 1:961-970.
105. Moser M.B., Moser E.I. Functional differentiation in the hippocampus. Hippocampus 1998, 8:608-619.
106. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry 1998, 55:580-592.
107. Naert G., Maurice T., Tapia-Arancibia L., Givalois L. Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 2007, 32:1062-1078.
108. Nakayama H., Jorgensen H.S., Raaschou H.O., Olsen T.S. The influence of age on stroke outcome. The Copenhagen Stroke Study. Stroke 1994, 25:808-813.
109. Ng F., Berk M., Dean O., Bush A.I. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int. J. Neuropsychopharmacol. 2008, 11:851-876.
110. Nitta A., Ohmiya M., Sometani A., Itoh M., Nomoto H., et al. Brain-derived neurotrophic factor prevents neuronal cell death induced by corticosterone. J. Neurosci. Res. 1999, 57:227-235.
111. Norata G.D., Marchesi P., Passamonti S., Pirillo A., Violi F., et al. Anti-inflammatory and anti-atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Atherosclerosis 2007, 191:265-271.
112. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
113. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., Shannon K.M., Nauert G.M., Perl D.P., Godbold J., Freeman T.B. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
114. Orimo M., Minamino T., Miyauchi H., Tateno K., Okada S., et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler. Thromb. Vasc. Biol. 2009, 29:889-894.
115. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
116. Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol. 1992, 140:621-628.
117. Parashar V., Rogina B. dSir2 mediates the increased spontaneous physical activity in flies on calorie restriction. Aging (Albany NY) 2009, 1:529-541.
118. Park I.H., Zhao R., West J.A., Yabuuchi A., Huo H., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451:141-146.
119. Parker J.A., Arango M., Abderrahmane S., Lambert E., Tourette C., et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 2005, 37:349-350.
120. Patchev V.K., Hassan A.H., Holsboer D.F., Almeida O.F. The neurosteroid tetrahydroprogesterone attenuates the endocrine response to stress and exerts glucocorticoid-like effects on vasopressin gene transcription in the rat hypothalamus. Neuropsychopharmacology 1996, 15:533-540.
121. Pearce R.K., Owen A., Daniel S., Jenner P., Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm. 1997, 104:661-677.
122. Peng C.H., Chiou S.H., Chen S.J., Chou Y.C., Ku H.H., et al. Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur. Neuropsychopharmacol. 2008, 18:128-140.
123. Penumathsa S.V., Maulik N. Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can. J. Physiol. Pharmacol. 2009, 87:275-286.
124. Penumathsa S.V., Koneru S., Samuel S.M., Maulik G., Bagchi D., et al. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic. Biol. Med. 2008, 45:1027-1034.
125. Perry T.L., Yong V.W. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 1986, 67:269-274.
126. Perry T.L., Godin D.V., Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency?. Neurosci. Lett. 1982, 33:305-310.
127. Price J.L., Ko A.I., Wade M.J., Tsou S.K., McKeel D.W., et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001, 58:1395-1402.
128. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996, 97:1916-1923.
129. Rao G.N., Lassegue B., Griendling K.K., Alexander R.W., Berk B.C. Hydrogen peroxide-induced c-fos expression is mediated by arachidonic acid release: role of protein kinase C. Nucleic Acids Res. 1993, 21:1259-1263.
130. Reznick A.Z., Gershon D. The effect of age on the protein degradation system in the nematode Turbatrix aceti. Mech. Ageing Dev. 1979, 11:403-415.
131. Robb E.L., Winkelmolen L., Visanji N., Brotchie J., Stuart J.A. Dietary resveratrol administration increases MnSOD expression and activity in mouse brain. Biochem. Biophys. Res. Commun. 2008, 372:254-259.
132. Rodrigue K.M., Raz N. Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. J. Neurosci. 2004, 24:956-963.
133. Rush B.D., Ruwart M.J., Day C.E. The mechanism of action of the hypocholesterolemic drug p-(1-adamantyloxy)-aniline. Atherosclerosis 1981, 39:345-351.
134. Sahay A., Hen R. Adult hippocampal neurogenesis in depression. Nat. Neurosci. 2007, 10:1110-1115.
135. Sahin E., Depinho R.A. Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature 2010, 464:520-528.
136. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
137. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2001, 301:805-809.
138. Sapolsky R.M. Why stress is bad for your brain. Science 1996, 273:749-750.
139. Sapolsky R.M. Glucocorticoids, stress, and their adverse neurological effects: relevance to aging. Exp. Gerontol. 1999, 34:721-732.
140. Sapolsky R.M., Krey L.C., McEwen B.S. The neuroendocrinology of stress and aging: the glucocorticoid cascade hypothesis. Endocr. Rev. 1996, 7:284-301.
141. Scherzinger E., Lurz R., Turmaine M., Mangiarini L., Hollenbach B., et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997, 90:549-558.
142. Schulz R., Beach S.R., Ives D.G., Martire L.M., Ariyo A.A., et al. Association between depression and mortality in older adults: the Cardiovascular Health Study. Arch. Intern. Med. 2000, 160:1761-1768.
143. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
144. Shetty, A.K., Hattiangady, B., Rao, M.S., Shuai, B. Deafferentation enhances neurogenesis in the young and middle aged hippocampus but not in the aged hippocampus. Hippocampus, in press.
145. Shindler K.S., Ventura E., Rex T.S., Elliott P., Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 2007, 48:3602-3609.
146. Shults C.W., Haas R. Clinical trials of coenzyme Q10 in neurological disorders. Biofactors 2005, 25:117-126.
147. Sinha K., Chaudhary G., Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002, 71:655-665.
148. Small S.A., Tsai W.Y., DeLaPaz R., Mayeux R., Stern Y. Imaging hippocampal function across the human life span: is memory decline normal or not?. Ann. Neurol. 2002, 51:290-295.
149. Smith A.D., Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp. Neurol. 2003, 184:31-39.
150. Smith M.A., Zhu X., Tabaton M., Liu G., McKeel D.W., et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J. Alzheimers Dis. 2010, 19:363-372.
151. Speck C.E., Kukull W.A., Brenner D.E., Bowen J.D., McCormick W.C., et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995, 6:366-369.
152. Stangl D., Thuret S. Impact of diet on adult hippocampal neurogenesis. Genes Nutr. 2009, 4:271-282.
153. Strohle A., Stoy M., Graetz B., Scheel M., Wittmann A., et al. Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder. Psychoneuroendocrinology 2010, 35:364-368.
154. Sullivan D.H., Johnson L.E. Nutrition and aging. Hazzard's Geriatric Medicine and Gerontology 2009, 452-453. McGraw Hill, New York. Sixth Edition. J.B. halter (Ed.).
155. Sumien N., Heinrich K.R., Shetty R.A., Sohal R.S., Forster M.J. Prolonged intake of coenzyme Q10 impairs cognitive functions in mice. J. Nutr. 2009, 139:1926-1932.
156. Sun A.Y., Wang Q., Simonyi A., Sun G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 2010, 41:375-383.
157. Tabar V., Panagiotakos G., Greenberg E.D., Chan B.K., Sadelain M., et al. Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain. Nat. Biotechnol. 2005, 23:601-606.
158. Tai L.K., Okuda M., Abe J., Yan C., Berk B.C. Fluid shear stress activates proline-rich tyrosine kinase via reactive oxygen species-dependent pathway. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1790-1796.
159. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
160. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
161. Tobin M.J., Snyder J.V. Cheyne-Stokes respiration revisited: controversies and implications. Crit. Care Med. 1984, 12:882-887.
162. Tortarolo M., Veglianese P., Calvaresi N., Botturi A., Rossi C., Giorgini A., Migheli A., Bendotti C. Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell. Neurosci. 2003, 23:180-192.
163. Ushio-Fukai M., Zafari A.M., Fukui T., Ishizaka N., Griendling K.K. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J. Biol. Chem. 1996, 271:23317-23321.
164. Uzunova V., Sheline Y., Davis J.M., Rasmusson A., Uzunov D.P., et al. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:3239-3244.
165. Valenzano D.R., Cellerino A. Resveratrol and the pharmacology of aging: a new vertebrate model to validate an old molecule. Cell Cycle 2006, 5:1027-1032.
166. Valenzano D.R., Terzibasi E., Genade T., Cattaneo A., Domenici L., et al. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 2006, 16:296-300.
167. van Ham T.J., Breitling R., Swertz M.A., Nollen E.A. Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. EMBO Mol. Med. 2009, 1:360-370.
168. Videbech P., Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am. J. Psychiatry 2004, 161:1957-1966.
169. Viswanathan M., Kim S.K., Berdichevsky A., Guarente L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell 2005, 9:605-615.
170. Vogelzangs N., Suthers K., Ferrucci L., Simonsick E.M., Ble A., et al. Hypercortisolemic depression is associated with the metabolic syndrome in late-life. Psychoneuroendocrinology 2007, 32:151-159.
171. Wallerath T., Li H., Godtel-Ambrust U., Schwarz P.M., Forstermann U. A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide 2005, 12:97-104.
172. Wang Q., Xu J., Rottinghaus G.E., Simonyi A., Lubahn D., et al. Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res. 2002, 958:439-447.
173. Wernig M., Zhao J.P., Pruszak J., Hedlund E., Fu D., et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5856-5861.
174. West M.J., Coleman P.D., Flood D.G., Troncoso J.C. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 1994, 344:769-772.
175. Whyte L., Huang Y.Y., Torres K., Mehta R.G. Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses. Cancer Res. 2007, 67:12007-12017.
176. Willett W.C., Stampfer M.J. Clinical practice. What vitamins should I be taking, doctor?. N. Engl. J. Med. 2001, 345:1819-1824.
177. Wolkowitz O.M., Reus V.I. Neurotransmitters, neurosteroids and neurotrophins: new models of the pathophysiology and treatment of depression. World J. Biol. Psychiatry 2003, 4:98-102.
178. Wolkowitz O.M., Epel E.S., Reus V.I., Mellon S.H. Depression gets old fast: do stress and depression accelerate cell aging?. Depress. Anxiety 2010, 27:327-338.
179. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2001, 2:343-351.
180. Wood J.G., Rogina B., Lavu S., Howitz K., Helfand S.L., et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004, 430:686-689.
181. Wu Z., Xu Q., Zhang L., Kong D., Ma R., et al. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem. Res. 2009, 34:1393-1400.
182. Yan L.J., Sohal R.S. Analysis of oxidative modification of proteins. Curr. Protoc. Cell. Biol. 2002, Chapter 7, Unit 7.9.
183. Yanagisawa D., Qi M., Kim D.H., Kitamura Y., Inden M., Tsuchiya D., Takata K., Taniguchi T., Yoshimoto K., Shimohama S., Akaike A., Sumi S., Inoue K. Improvement of focal ischemia-induced rat dopaminergic dysfunction by striatal transplantation of mouse embryonic stem cells. Neurosci. Lett. 2006, 407:74-79.
184. Yang D., Zhang Z.J., Oldenburg M., Ayala M., Zhang S.C. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008, 26:55-63.
185. Yankner B.A., Lu T., Loerch P. The aging brain. Annu. Rev. Pathol. 2008, 3:41-66.
186. Yeh L.J. Physical therapy for common diseases in the elderly. JPTA ROC 1991, 16:125-132.
187. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
188. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
189. Zemlan F.P., Thienhaus O.J., Bosmann H.B. Superoxide dismutase activity in Alzheimer's disease: possible mechanism for paired helical filament formation. Brain. Res. 1989, 476:160-162.
190. Zhang Z.G., Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009, 8:491-500.